The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA.
Miknyoczki SJ, et al.
Clin Cancer Res. 1999 Aug;5(8):2205-12.
Clin Cancer Res. 1999.
PMID: 10473107
We have previously demonstrated the aberrant expression of the Trk receptors (Trks A, B, and C), enhanced tumor stromal expression of neurotrophins in primary PDAC specimens and human PDAC-derived cell lines, and a dose-dependent biological response of PDAC cells (in vitro invasi …
We have previously demonstrated the aberrant expression of the Trk receptors (Trks A, B, and C), enhanced tumor stromal expression of neurot …